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Abstract: Hsp27, Hsp60, Hsp70, and Hsp90 are chaperones that play a crucial role in cellular
homeostasis and differentiation, but they may be implicated in carcinogenesis. Follicular neoplasms
of the thyroid include follicular adenoma and follicular carcinoma. The former is a very frequent benign
encapsulated nodule, whereas the other is a nodule that infiltrates the capsule, blood vessels and the
adjacent parenchyma, with a tendency to metastasize. The main objective was to assess the potential
of the Hsps in differential diagnosis and carcinogenesis. We quantified by immunohistochemistry
Hsp27, Hsp60, Hsp70, and Hsp90 on thin sections of human thyroid tissue with follicular adenoma or
follicular carcinoma, comparing the tumor with the adjacent peritumoral tissue. Hsp60, Hsp70, and
Hsp90 were increased in follicular carcinoma compared to follicular adenoma, while Hsp27 showed
no difference. Histochemical quantification of Hsp60, Hsp70, and Hsp90 allows diagnostic distinction
between follicular adenoma and carcinoma, and between tumor and adjacent non-tumoral tissue.
The quantitative variations of these chaperones in follicular carcinoma suggest their involvement in
tumorigenesis, for instance in processes such as invasion of thyroid parenchyma and metastasization.
Keywords: Hsp27; Hsp60; Hsp70; Hsp90; molecular chaperone; chaperonopathies; thyroid; follicular
adenoma; follicular carcinoma; differential diagnosis; carcinogenesis
1. Introduction
Thyroid tumors are the most frequent endocrine malignancies and their incidence is steadily
increasing [1]. They are divided into epithelial and non-epithelial tumors. Follicular neoplasms of the
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thyroid gland include benign follicular adenoma (FA) and follicular carcinoma (FC) [2]. FA is the most
common benign thyroid tumor and occurs in follicular cells. Macroscopically, it may appear as a single
nodule, whose diameter can vary from a few millimetres to a few centimetres, surrounded by a single
capsule. Microscopically, it is characterized by the proliferation of many follicles surrounded by a
capsule and, depending on their size the adenomas can be sorted into normofollicular, microfollicular,
macrofollicular, and solid-trabecular.
Among thyroid carcinomas, FC is the second most common epithelial tumor after papillary
carcinoma, occurring late in life, with the fifth and sixth decades being the most affected, and is more
aggressive than papillary carcinoma [3]. Macroscopically it appears as a thyroid nodule of variable
diameter and may or may not possess a capsule. Microscopically, FC consists of a proliferation of
follicles, similarly to FA, but the neoplastic follicles invade the tumor capsule when present, penetrating
into blood vessels and/or the adjacent normal thyroid tissue, a feature that can only be appreciated
with histological but not with cytological techniques [4].
Immunohistochemical analysis does not usually allow the differentiation between benign and
malignant lesions and, as a consequence, the majority of patients with these lesions are referred to
surgery without a precise diagnosis. For this reason, it is necessary to improve the preoperative
diagnosis also because no clinical, radiological, or laboratory test currently available is sufficiently
sensitive and specific to distinguish benign from malignant follicular lesions detected by fine-needle
aspiration [5].
Molecular chaperones are the main components of the chaperoning system with canonical and
non-canonical functions [6,7]. The former functions pertain to maintenance of protein homeostasis and
include assisting in the: folding of nascent polypeptides as soon as they emerge from the ribosome and
until they reach their native and biologically active tridimensional structure; prevention of protein
misfolding and aggregation; translocation of proteins from one cell compartment to another; and
driving damaged or unnecessary proteins toward degradation [8–12].
Many chaperones are heat shock proteins (Hsp) but although not all Hsp are chaperones the terms
molecular chaperone (or chaperone in short) and Hsp are used as synonyms. Chaperones are classified
according to molecular weight [7] and designated variously, which causes confusion, and because of
this, attempts at nomenclature standardization have been made [13].
Although chaperones are considered essentially cytoprotective, it is now known that they
can also be pathogenic if abnormal in structure, or location, or quantity, causing diseases named
chaperonopathies, including several types of cancer [7,14].
Some chaperones are increased in various cancers with the magnitude of the increase being closely
associated with prognosis and with resistance to anticancer therapy, the former being worse and the
latter being higher as the chaperones increase is bigger [15,16].
There are few data in the literature on the role of Hsp in thyroid cancer, for example Hsp27 was
increased in anaplastic carcinoma [17], and in papillary carcinoma, in which it was induced by 17
β-estradiol, which facilitates proliferation and confers resistance to apoptosis [18]. In this study, we
performed immunomorphological analysis on samples of FA and FC to evaluate, for the first time to
our knowledge, the tissue levels of Hsp27, Hsp60, Hsp70, and Hsp90. We focused on these chaperones
based on the fact that they are implicated in chaperonopathies, including carcinogenesis [15,19].
2. Materials and Methods
2.1. Sample Collection
Formalin-fixed and paraffin-embedded thyroid tissue of human FA and FC (10 samples for each
group) were retrieved from the archives of the Department of Human Pathology of the University
of Palermo to perform immunohistochemical assays for Hsp27, Hsp60, Hsp70, and Hsp90. These
samples were from patients who had undergone thyroidectomy surgery in the Department of Surgical,
Oncological and Oral Sciences at the University of Palermo (Table 1). The experiments related to this
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study were conducted as part of the study project approved by the Ethics Committee of University
Hospital AUOP Paolo Giaccone of Palermo (N◦ 05/2017 of 05/10/2017).
Table 1. Patient demographics and tumor characteristics.
Sex Age (yrs)* Localization
Thyroid Weight
(g)
Nodules Size
(mm)
FOLLICULAR ADENOMA
M 27 Right lobe 35 17
F 39 Right lobe 15 28
F 69 Left lobe 30 24
M 46 Right lobe 35 32
F 73 Left lobe 120 30
F 55 Left lobe 20 20
F 67 Right lobe 40 22
M 35 Left lobe 55 38
F 29 Isthmus 60 42
F 48 Right lobe 70 15
FOLLICULAR CARCINOMA Stage(AJCC/TNM)
F 41 Left lobe 45 25 I
F 29 Right lobe 35 30 I
M 62 Right lobe 80 35 I
F 51 Right lobe 50 40 I
F 48 Isthmus 20 28 I
F 39 Left lobe 25 25 I
M 67 Right lobe 45 38 II
F 57 Right lobe 60 22 II
F 29 Left lobe 25 19 I
F 61 Right lobe 30 41 I
*Abbreviations. Yrs, years; M, male; F, female; AJCC, American Joint Committee on Cancer;
TNM, Tumor-Nodes-Metastasis.
2.2. Immunohistochemistry
Immunohistochemical experiments were performed on 5-micron thick sections of
paraffin-embedded tissue, obtained with a cutting microtome. The slides were dewaxed in xylene for
30 min at 60 ◦C and rehydrated, at 22 ◦C, by sequential immersion in a graded series of alcohols and
transferred into distilled water for 5 min. Then, the sections were incubated for 8 min in Sodium Citrate
Buffer (pH 6) at 95 ◦C for antigen unmasking and immersed for 8 min in acetone at −20 ◦C to prevent
the detachment of the sections from the slide. After a wash of sections with PBS (Phosphate Buffered
Saline pH 7.4) at 22 ◦C for 5 min, the experiments for Hsp60, Hsp70, and Hsp90 were performed
applying a streptavidin–biotin complex method, using Histostain®-Plus 3rd Gen IHC Detection Kit
(Life Technologies, Frederik, MD, USA; Cat. No. 85–9073). Therefore, the sections were treated for
5 min with Peroxidase Quenching Solution (reagent A of Histostain®-Plus 3rd Gen IHC Detection Kit,
Life Technologies) to inhibit endogenous peroxidase activity, and after another wash with PBS at 22 ◦C
for 5 min, were treated with blocking solution (reagent B of Histostain®-Plus 3rd Gen IHC Detection
Kit, Life Technologies) for 10 min to block non-specific antigenic sites. Subsequently, the sections
were incubated overnight at 22 ◦C, with a primary antibody against human Hsp60 (rabbit anti-Hsp60
polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, cat. N◦: sc-13966, dilution
1:300), human Hsp70 (mouse anti-Hsp70 monoclonal antibody, clone W27, Santa Cruz Biotechnology,
Inc, Santa Cruz, CA, USA, cat. N◦: sc-24, dilution 1:200) and human Hsp90 (mouse anti-Hsp90
monoclonal antibody, clone F-8, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, cat. N◦: sc-13119,
dilution 1:200). Appropriate positive and negative (isotype) controls, were run concurrently. The
following day, after a wash with PBS at 22 ◦C for 5 min, the sections were incubated with a universal
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biotinylated secondary antibody (Biotinylated Secondary Antibody reagent C Histostain®-Plus 3rd
Gen IHC Detection Kit, Life Technologies) for 10 min. After a subsequent washing with PBS for 5 min,
the sections were incubated with streptavidin-peroxidase complex (Streptavidin-Peroxidase Conjugate
reagent D Histostain®-Plus 3rd Gen IHC Detection Kit, Life Technologies) for 10 min, and following
a further washing in PBS for 5 min, the slides were incubated in the dark for 5 min with the DAB
chromogen (diaminobenzidine) (DAB chromogen reagents E1 and E2 Histostain®-Plus 3rd Gen IHC
Detection Kit, Life Technologies). The experiments for Hsp27 were performed using an IHC goat kit
(Cell & Tissue Staining Kit, R&D Systems, Inc., Minneapolis, MN, USA, Cat N◦ CTS008). Sections,
after deparaffinization, were treated at 22 ◦C for 5 min with Peroxidase Blocking Reagent (Cell &
Tissue Staining Kit, R&D Systems, Inc.) to inhibit endogenous peroxidase activity and after another
wash with PBS for 5 min, with a Serum Blocking Reagent D (Cell & Tissue Staining Kit, R&D Systems,
Inc.) for 15 min to block non-specific antigenic sites. Since the detection is based on the formation of
Avidin-Biotin complex, the sections were treated with Avidin Blocking Reagent (Cell & Tissue Staining
Kit, R&D Systems, Inc.) at 22◦C for 15 min. After a wash with PBS, the sections were incubated with
Biotin Blocking Reagent for 15′ (Cell & Tissue Staining Kit, R&D Systems, Inc.). After another wash
with PBS, the sections were incubated at 22 ◦C overnight, with a primary antibody against human
Hsp27 (goat anti-Hsp27 polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA,
cat. N◦: sc-1048, dilution 1:150). For all samples, appropriate positive and negative (isotype) controls
were run concurrently. So the samples were washed at 22 ◦C three times in PBS for 15 min/wash, and
then the sections were incubated with Biotinylated Secondary Antibody (Cell & Tissue Staining Kit,
R&D Systems, Inc.) for 40 min most often (the length of this incubation time varies depending on the
thickness of the section). After that, the slides were washed three times in PBS for 15 min/wash. The
high detection sensitivity of this method is obtained by using premium quality biotinylated secondary
antibodies and High Sensitivity Streptavidin-conjugated HRP (HSS-HRP). HSS is a chemical analog
of Streptavidin that interacts only with Biotin bound to secondary antibodies. The sections were
incubated at 22 ◦C with HSS-HRP (Vial B, Cell & Tissue Staining Kit, R&D Systems, Inc.) for 30 min.
For all samples, the visualization is based on enzymatic conversion of chromogenic substrates 3,3′
Diaminobenzidine (DAB) into a colored precipitate (brown), by horseradish peroxidase (HRP) at the
sites of antigen localization, after two subsequent washing with PBS for 2 min/wash, the slides were
incubated in the dark for 5 min with the DAB chromogen (200 µL of DAB chromogen solution were
required to cover tissue section on a single slide). Two drops of DAB Crhomogen were added to 2 mL
of DAB Chromogen Buffer (Cell & Tissue Staining Kit, R&D Systems, Inc.).
The nuclei were counterstained with hematoxylin (Hematoxylin aqueous formula, REF
05-06012/LN. Cat. S2020, Bio-Optica, Milano, Italy). Finally, the slides were mounted for observation
with coverslips using a permanent mounting medium (Vecta Mount, H-5000, Vector Laboratories, Inc.
Burlingame, CA, USA). The observation of the sections was carried out with an optical microscope
(Leica DM 5000 B, Leica Microsystems Srl, Buccinasco (MI), Italy) connected to a digital camera
(Leica DC 300F).
Two independent observers (F.C, and F.R) examined all specimens on two separate occasions
and performed a quantitative analysis to quantify the percentage of epithelial cells positive for Hsp27,
Hsp60, Hsp70, and Hsp90. All the observations were done at a magnification of 400× and the
percentage of positive cells was calculated in a high-power field (HPF) and repeated for 10 HFP.
The immunopositivity evaluation is expressed as average percentage of all immuno-quantifications
performed in each case for each Hsp. Statistical analyses were carried out using the GraphPad Prism 4.0
package (GraphPad Inc., San Diego, CA, USA). One-way ANOVA analysis of variance with Bonferroni
post-hoc multiple comparisons was used to detect significant statistical differences. All data are
reported as the means ± SD, and the level of statistical significance was set at p ≤ 0.05.
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2.3. Results
The presence and levels of Hps27, Hsp60, Hps70 and, Hsp90 were determined in the tumor
tissue itself and in the adjacent parenchyma (AP) of FA and FC. The immunopositivity for Hsp27 was
observed in the cytoplasm and the nucleus in tumoral cells while only in the cytoplasm in the cells of
the adjacent parenchyma. It was high in all specimens and it did not show significant quantitative
differences between the specimens or tissue type: it was 73% in FA and 70% in its AP, and 68% in FC
and 47% in its AP (Figure 1).
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Figure 1. Hsp27 Immunohistochemistry. (A) Representative images of immunohistochemical results
for Hsp27. Magnification 200×; scale bar 100 µm. (B) The histogram shows statistical results for
the immunohistochemical evaluation for Hsp27 in follicular adenoma (FA), adj cent pa nchyma of
follicular adenoma (AP FA), follicular carcinoma (FC) and adjacent parenchym of follicul carcinoma
(AP FC). Data are presented as mean +SD.
The Hsp60 tissue levels were 33% in FA and 7% in its AP with a significant difference (p ≤ 0.01),
and in FC the immunopositivity was 74% and 6% in its AP with a significant difference (p ≤ 0.001).
In the FA and FC epithelial cells, the immu opositivity was diffuse in the cytoplasm while in the
epithelial cells of the AP was al o in the cytoplasm but mild and granular. Statistical analysis also,
showed a significant difference between FA and FC (p ≤ 0.001) (Figure 2).
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Figure 2. Hsp60 Immunohistochemistry. (A) Representative images of immunohistochemical results
for Hsp60. Magnification 200X; scale bar 100 µm. (B) The histogram shows statistical results for
the immunohistochemical evaluation for Hsp60 in follicular adenoma (FA), adjacent parenchyma of
follicular adenoma (AP FA), follicular carcinoma (FC) and adjacent parenchyma of follicular carcinoma
(AP FC). Data are presented as the mean +SD. * p ≤ 0.0001, # p ≤ 0.01.
The results for Hsp70 showed a positivi y of 18% and 8% in FA and its AP, respectively, with no
statistical difference, and of 55% and 7% in FC and its AP, respectively, with a statistical difference
(p ≤ 0.001). The epithelial cells of FC showed a high cytoplasmic positivity while those of FA and the
AP of both neoformations, showed a mild and pointed immunopositivity. Statistical analysis also
showed a significant difference between FA and FC (p ≤ 0.001) (Figure 3).
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Figure 3. Hsp70 Immunohistochemistry. (A) Representative images of immunohistochemical results
for Hsp70. Magnification 200×; scale bar 100 µm. (B) The histogram shows statistical results for
the immunohistochemical evaluation for Hsp70 in follicular adenoma (FA), adjacent parenchyma of
follicular adenoma (AP FA), follicular carcinoma (FC) and djacent parenchyma of follicular carcinoma
(AP FC). Data are presented as the mean +SD. * p ≤ 0.0001.
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The tissue levels of Hsp90 were 25% in FA and 15% in its AP, and were 56% in FC and 33% in
its AP with no statistical difference. In all specimens the immunopositivity was cytoplasmic, intense
in the FC and FA cells while mild in the cells of the AP. Statistical analysis also showed a significant
difference between FA and FC (p ≤ 0.05) (Figure 4).
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the immunohistochemical evaluation for Hsp90 in follicular adenoma (FA), adjacent parenchyma of
follicular adenoma (AP FA), follicular carcinoma (FC) and adjacent parenchyma of follicular carcinoma
(AP FC). Data are presented as the mean +SD. * p < 0.05.
Our immunohistochemical observation was also dedicated to the evaluation of the intracellular
localization of the Hsp immunopositivity. We observed an ac umulation of Hsp60, Hsp70, and Hsp90
in the cytoplasm and of Hsp27 in the cytoplasm and in the nu leus.
3. Discussion
In this work, we studied the immunohistochemical levels of Hps27, Hsp60, Hps70, and Hsp90 in
human thyroid tissue with follicular adenoma (FA) and follicular carcinoma (FC). FC is characterized
by the ability to invade the tumor capsule when this is present and forcing its way inside blood vessels
and in the adjacent normal thyroid tissue. This char cteristic distinguishes FC from FA. I eneral,
the pathol gical condition of cancer is characterized by an imbalance between cell proliferation and
differentiation. A physiological balance betwee cell proliferation and differentiation is essential to
ensure proper gr wth and development of multicellular organisms, and to maintain adult tissue and
organ homeostasis. It is of fundamental interest in c cer pathology to understand the mechanisms
underpi ni g the origin of the loss of cell differentiation capability and th inductio of m lignancy
progressio . Molecular chaperones play a key role in the maintenance of cellular a d tissue homeostasis
and in the regulation of organ remodelli g [20–23]. However, when abnormal in structure and/or
quantity nd/or function, and/or location, chaperones can cause disease, the chaperonopathies [7,14],
and nu erous scientific reports showed their involvement in the pathogen sis and progression of
various human neoplasms [15,19,24]. High tissue levels of Hsps are often associated with ca cer
progression and invasiveness, as shown by studies in which it was suggested that th se pr teins are
augmented in some types of tum rs with tendency to invade surrounding ti sues and to spread to
distant organs [19,25–27].
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Hsp27 was initially characterized as a chaperone that facilitates the refolding of damaged proteins
in response to heat shock. Further investigations revealed that Hsp27 also responds to oxidative
and chemical stressors, mainly acting as an antioxidant and antiapoptotic agent. It was observed
that an increase of Hsp27 levels is transiently induced at specific stages during development and
cell differentiation and occurs concomitantly with the differentiation-associated decrease of cellular
proliferation [28,29]. Other studies reported that Hsp27 is augmented in different types of tumors and
its levels are directly associated with a more aggressive malignant behavior (cancer cell proliferation,
invasiveness, and metastasis) and resistance to chemotherapy [30,31]. Furthermore, Hsp27 mediates
endothelial cell mobility, improving angiogenesis [32].
The eukaryotic Hsp60 resides and works in the mitochondrial matrix where, together with its
co-chaperonin Hsp10, drives the proper folding of proteins destined to the mitochondrial matrix. In
addition to this intramitochondrial function, Hsp60 plays a role in other cellular processes beyond
the mitochondrion, for instance in the cytosol, plasma-cell membrane, extracellular environment,
and biological fluids) [33]. Hsp60 seems to be directly or indirectly involved in carcinogenesis in
different organs, since its levels change during the carcinogenetic steps [15,24]. Hsp60 levels are
increased in various tumors such as colorectal cancer, liver and uterine cervical cancers and its levels
are correlated with cancer progression, which makes this chaperonin a useful biomarker indicating
poor prognosis [34,35].
There are many reports of a strong association of Hsp70 with cancer development. For instance, it
promotes carcinogenesis by acting as survival factor owing to its tumor-associated expression and
anti-apoptotic effects [36]. Hsp70 abundance gives the neoplasm greater invasiveness [37].
Hsp90 is also augmented in various cancers, apparently playing important roles in cancer
biology by regulating tumor growth, invasion, metastasis, angiogenesis, and apoptosis, and induces
neoangiogenesis by stabilizing vascular endothelial growth factor and nitric oxide syntheses [38–40].
In light of what is available in the literature in the field of Hsp and cancer, very briefly summarized
in the preceding paragraphs, we decided to evaluate the tissue levels of the four molecular chaperones
discussed above, simultaneously, in samples of thyroid follicular neoplasms, about which there is little
information. We also observed the localization of these Hsp in tumor cells to evaluate their possible
localization change.
Hsp27 levels did not show significant quantitative differences between the groups studied. This
result is in contrast with the data present in the literature on other types of tumors, which indicates that
the thyroid tumors deserve detailed analysis to elucidate the basis for this unique feature regarding
Hsp27. However, even if we did not find a quantitative difference, we observed a nuclear localization
that, according to the data in the literature, would be linked to the phosphorylation of the chaperone [41].
Conversely, we observed a higher immunopositivity of Hsp60, Hsp70, and Hsp90 in FC compared
to FA and their adjacent parenchyma. These data are in agreement with what has been published in
the literature on other types of tumors. The increase of Hsp60 and Hsp70 in FC suggest its implication
in carcinogenesis and in the progression of this tumor. Hsp60 and Hsp70 levels in FC were higher
compared to adjacent parenchyma levels. In normal cells, Hsp 60 is detected in the mitochondria
while in tumoral cells it is abundant in the cytoplasm. These data are interesting because both Hsps
could be considered tumor tissue markers. Likewise, the higher levels of Hsp90 might indicate its
implication in the process of FC invasion of surrounding tissue. This could be attributed to the known
stabilizing effects of Hsp90 on matrix metalloproteinases, which would favor tumor infiltration and
invasion [42,43].
In conclusion, our immunohistochemical data suggest an involvement of Hsp60, Hsp70, and
Hsp90 in the mechanisms of carcinogenesis of thyroid follicular carcinoma. The immunomorphological
observation showed a change in cellular localization of the Hsps studied. This pattern is found in
various carcinogenic processes [19,24]. It is necessary to continue these studies to clarify the molecular
mechanisms underlying the increase in tissue levels of these chaperones in this human cancer. In this
regard, determination of chaperone-gene expression levels and elucidation of post-transcriptional
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mechanisms that might be involved in augmenting the levels of the chaperones in thyroid tumors
seem to be the most promising approaches toward finding points of attacks by anti-cancer agents.
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